AR022061A1
(es)
*
|
1998-08-10 |
2002-09-04 |
Boehringer Ingelheim Ca Ltd |
Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
|
UA74546C2
(en)
*
|
1999-04-06 |
2006-01-16 |
Boehringer Ingelheim Ca Ltd |
Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
|
US6608027B1
(en)
|
1999-04-06 |
2003-08-19 |
Boehringer Ingelheim (Canada) Ltd |
Macrocyclic peptides active against the hepatitis C virus
|
IL151934A0
(en)
*
|
2000-04-05 |
2003-04-10 |
Schering Corp |
Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising n-cyclic p2 moieties
|
NZ521456A
(en)
|
2000-04-19 |
2004-07-30 |
Schering Corp |
Macrocyclic NS3-Serine protease inhibitors of hepatitis C virus comprising alkyl and aryl alanine P2 moieties
|
BR0112666A
(pt)
|
2000-07-21 |
2003-06-10 |
Schering Corp |
Peptìdeos como inibidores de ns3-serina protease de vìrus da hepatite c
|
AR029851A1
(es)
|
2000-07-21 |
2003-07-16 |
Dendreon Corp |
Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
|
DK1385870T3
(da)
|
2000-07-21 |
2010-07-05 |
Schering Corp |
Peptider som inhibitorer af NS3-serinprotease fra hepatitis C-virus
|
SV2003000617A
(es)
*
|
2000-08-31 |
2003-01-13 |
Lilly Co Eli |
Inhibidores de la proteasa peptidomimetica ref. x-14912m
|
US6846806B2
(en)
|
2000-10-23 |
2005-01-25 |
Bristol-Myers Squibb Company |
Peptide inhibitors of Hepatitis C virus NS3 protein
|
IL155842A0
(en)
|
2000-12-12 |
2003-12-23 |
Schering Corp |
Diaryl peptides as ns3-serine protease inhibitors of hepatitis c virus
|
KR100926244B1
(ko)
*
|
2001-07-11 |
2009-11-12 |
버텍스 파마슈티칼스 인코포레이티드 |
브릿지된 바이사이클릭 세린 프로테아제 억제제
|
AU2002348414B2
(en)
*
|
2001-10-24 |
2009-10-01 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine protease, particularly hepatitis C virus NS3-NS4A protease, incorporating a fused ring system
|
ES2332778T3
(es)
*
|
2002-01-23 |
2010-02-12 |
Schering Corporation |
Compuestos de prolina como inhibidores de la proteasa serina ns3 para uso en el tratamiento de infeccion por el virus de la hepatitis c.
|
US7119072B2
(en)
|
2002-01-30 |
2006-10-10 |
Boehringer Ingelheim (Canada) Ltd. |
Macrocyclic peptides active against the hepatitis C virus
|
US6642204B2
(en)
|
2002-02-01 |
2003-11-04 |
Boehringer Ingelheim International Gmbh |
Hepatitis C inhibitor tri-peptides
|
US7091184B2
(en)
|
2002-02-01 |
2006-08-15 |
Boehringer Ingelheim International Gmbh |
Hepatitis C inhibitor tri-peptides
|
EP2468744A2
(en)
|
2002-04-11 |
2012-06-27 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
|
MY140680A
(en)
|
2002-05-20 |
2010-01-15 |
Bristol Myers Squibb Co |
Hepatitis c virus inhibitors
|
AU2003248535A1
(en)
|
2002-05-20 |
2003-12-12 |
Bristol-Myers Squibb Company |
Heterocyclicsulfonamide hepatitis c virus inhibitors
|
US6878722B2
(en)
|
2002-05-20 |
2005-04-12 |
Bristol-Myers Squibb Company |
Substituted cycloalkyl P1′ hepatitis C virus inhibitors
|
AU2003299519A1
(en)
|
2002-05-20 |
2004-05-04 |
Bristol-Myers Squibb Company |
Hepatitis c virus inhibitors
|
US20050075279A1
(en)
|
2002-10-25 |
2005-04-07 |
Boehringer Ingelheim International Gmbh |
Macrocyclic peptides active against the hepatitis C virus
|
JP4550824B2
(ja)
*
|
2003-03-05 |
2010-09-22 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
C型肝炎抑制化合物
|
CA2516018C
(en)
|
2003-03-05 |
2011-08-23 |
Boehringer Ingelheim International Gmbh |
Hepatitis c inhibitor peptide analogs
|
KR100971347B1
(ko)
*
|
2003-03-08 |
2010-07-20 |
주식회사유한양행 |
씨형 간염바이러스 감염 치료용 엔에스3 프로테아제 억제제
|
US7148347B2
(en)
|
2003-04-10 |
2006-12-12 |
Boehringer Ingelheim International Gmbh |
Process for preparing macrocyclic compounds
|
US7176208B2
(en)
|
2003-04-18 |
2007-02-13 |
Enanta Pharmaceuticals, Inc. |
Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
|
BRPI0410456B8
(pt)
|
2003-05-21 |
2021-05-25 |
Boehringer Ingelheim Int |
compostos inibidores de hepatite c, composição farmacêutica, uso dos mesmos, bem como artigo de fabricação
|
CA2536570A1
(en)
|
2003-08-26 |
2005-03-10 |
Schering Corporation |
Novel peptidomimetic ns3-serine protease inhibitors of hepatitis c virus
|
TWI359147B
(en)
|
2003-09-05 |
2012-03-01 |
Vertex Pharma |
Inhibitors of serine proteases, particularly hcv n
|
AU2004274051A1
(en)
|
2003-09-22 |
2005-03-31 |
Boehringer Ingelheim International Gmbh |
Macrocyclic peptides active against the hepatitis C virus
|
MXPA06003455A
(es)
|
2003-09-26 |
2006-05-31 |
Schering Corp |
Inhibidores macrociclicos de la serina proteasa ns3 del virus de la hepatitis c.
|
CN102020697B
(zh)
|
2003-10-14 |
2014-10-29 |
F·霍夫曼-罗须公司 |
作为hcv复制抑制剂的巨环羧酸和酰基磺酰胺
|
WO2005043118A2
(en)
|
2003-10-27 |
2005-05-12 |
Vertex Pharmaceuticals Incorporated |
Drug discovery method
|
AU2004285019B9
(en)
|
2003-10-27 |
2011-11-24 |
Vertex Pharmaceuticals Incorporated |
HCV NS3-NS4A protease resistance mutants
|
US7132504B2
(en)
|
2003-11-12 |
2006-11-07 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7135462B2
(en)
|
2003-11-20 |
2006-11-14 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
WO2005051980A1
(en)
*
|
2003-11-20 |
2005-06-09 |
Schering Corporation |
Depeptidized inhibitors of hepatitis c virus ns3 protease
|
US7309708B2
(en)
|
2003-11-20 |
2007-12-18 |
Birstol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
ATE424926T1
(de)
|
2003-12-08 |
2009-03-15 |
Boehringer Ingelheim Int |
Abtrennung von ruthenium-nebenprodukten durch behandlung mit überkritischen flüssigkeiten
|
GB0500020D0
(en)
|
2005-01-04 |
2005-02-09 |
Novartis Ag |
Organic compounds
|
CA2549851C
(en)
|
2004-01-21 |
2012-09-11 |
Boehringer Ingelheim International Gmbh |
Macrocyclic peptides active against the hepatitis c virus
|
DK1713823T3
(da)
|
2004-01-30 |
2010-03-08 |
Medivir Ab |
HCV NS-3 serinproteaseinhibitorer
|
US7582770B2
(en)
|
2004-02-20 |
2009-09-01 |
Boehringer Ingelheim International Gmbh |
Viral polymerase inhibitors
|
EP1719773B1
(en)
|
2004-02-24 |
2009-04-15 |
Japan Tobacco, Inc. |
Fused heterotetracyclic compounds and use tehreof as hcv polymerase inhibitor
|
US20070049593A1
(en)
|
2004-02-24 |
2007-03-01 |
Japan Tobacco Inc. |
Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
|
EP1737821B1
(en)
|
2004-02-27 |
2009-08-05 |
Schering Corporation |
3,4-(cyclopentyl)-fused proline compounds as inhibitors of hepatitis c virus ns3 serine protease
|
KR20060124725A
(ko)
|
2004-02-27 |
2006-12-05 |
쉐링 코포레이션 |
C형 간염 바이러스 ns3 프로테아제의 억제제
|
ES2327544T3
(es)
|
2004-02-27 |
2009-10-30 |
Schering Corporation |
Compuestos novedosos como inhibidores de serina proteasa ns3 de virus de hepetitis c.
|
RS51394B
(en)
|
2004-02-27 |
2011-02-28 |
Schering Corporation |
SUMPOR COMPOUNDS AS INHIBITORS OF NS3 SERINE PROTEASE HEPATITIS C VIRUS
|
BRPI0508095A
(pt)
|
2004-02-27 |
2007-07-17 |
Schering Corp |
compostos como inibidores de ns3 serina protease do vìrus da hepatite c
|
US7816326B2
(en)
|
2004-02-27 |
2010-10-19 |
Schering Corporation |
Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease
|
ATE459638T1
(de)
|
2004-03-15 |
2010-03-15 |
Boehringer Ingelheim Int |
Verfahren zur herstellung makrocyclischer dipeptide, die sich für die behandlung von hepatitis-c-virusinfektionen eignen
|
WO2005095403A2
(en)
*
|
2004-03-30 |
2005-10-13 |
Intermune, Inc. |
Macrocyclic compounds as inhibitors of viral replication
|
EP1773868B1
(en)
|
2004-05-20 |
2009-07-15 |
Schering Corporation |
Substituted prolines as inhibitors of hepatitis c virus ns3 serine protease
|
JP5156374B2
(ja)
|
2004-05-25 |
2013-03-06 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
非環式hcvプロテアーゼインヒビターの調製方法
|
CA2573346C
(en)
|
2004-07-20 |
2011-09-20 |
Boehringer Ingelheim International Gmbh |
Hepatitis c inhibitor peptide analogs
|
UY29016A1
(es)
|
2004-07-20 |
2006-02-24 |
Boehringer Ingelheim Int |
Analogos de dipeptidos inhibidores de la hepatitis c
|
US7597884B2
(en)
|
2004-08-09 |
2009-10-06 |
Alios Biopharma, Inc. |
Hyperglycosylated polypeptide variants and methods of use
|
CA2577812A1
(en)
|
2004-08-27 |
2006-03-09 |
Schering Corporation |
Acylsulfonamide compounds as inhibitors of hepatitis c virus ns3 serine protease
|
WO2006030892A1
(ja)
*
|
2004-09-17 |
2006-03-23 |
Nippon Shinyaku Co., Ltd. |
複素環化合物の製造方法
|
AU2005291918A1
(en)
|
2004-10-01 |
2006-04-13 |
Vertex Pharmaceuticals Incorporated |
HCV NS3-NS4A protease inhibition
|
US7659263B2
(en)
|
2004-11-12 |
2010-02-09 |
Japan Tobacco Inc. |
Thienopyrrole compound and use thereof as HCV polymerase inhibitor
|
US7323447B2
(en)
|
2005-02-08 |
2008-01-29 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
WO2006096652A2
(en)
|
2005-03-08 |
2006-09-14 |
Boehringer Ingelheim International Gmbh |
Process for preparing macrocyclic compounds
|
US7592336B2
(en)
|
2005-05-10 |
2009-09-22 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
AP2007004245A0
(en)
|
2005-05-13 |
2007-12-31 |
Virochem Pharma Inc |
Compounds and methods for the treatment or prevention of flavivirus infections
|
US7601686B2
(en)
|
2005-07-11 |
2009-10-13 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
KR101294467B1
(ko)
|
2005-07-25 |
2013-09-09 |
인터뮨, 인크. |
C형 간염 바이러스 복제의 신규 거대고리형 억제제
|
PE20070211A1
(es)
|
2005-07-29 |
2007-05-12 |
Medivir Ab |
Compuestos macrociclicos como inhibidores del virus de hepatitis c
|
US8076365B2
(en)
|
2005-08-12 |
2011-12-13 |
Boehringer Ingelheim International Gmbh |
Viral polymerase inhibitors
|
WO2007030656A1
(en)
|
2005-09-09 |
2007-03-15 |
Boehringer Ingelheim International Gmbh |
Ring-closing metathesis process for the preparation of macrocyclic peptides
|
AU2006301966A1
(en)
|
2005-10-11 |
2007-04-19 |
Array Biopharma, Inc. |
Compounds and methods for inhibiting hepatitis C viral replication
|
US7772183B2
(en)
|
2005-10-12 |
2010-08-10 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7741281B2
(en)
|
2005-11-03 |
2010-06-22 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7705138B2
(en)
|
2005-11-11 |
2010-04-27 |
Vertex Pharmaceuticals Incorporated |
Hepatitis C virus variants
|
US7816348B2
(en)
|
2006-02-03 |
2010-10-19 |
Boehringer Ingelheim International Gmbh |
Viral polymerase inhibitors
|
US8017612B2
(en)
|
2006-04-18 |
2011-09-13 |
Japan Tobacco Inc. |
Piperazine compound and use thereof as a HCV polymerase inhibitor
|
RU2419626C2
(ru)
|
2006-05-23 |
2011-05-27 |
Айрм Ллк |
Соединения и композиции в качестве ингибиторов протеазы, активирующей каналы
|
WO2008008776A2
(en)
|
2006-07-11 |
2008-01-17 |
Bristol-Myers Squibb Company |
Hepatitis c virus inhibitors
|
EP1886685A1
(en)
|
2006-08-11 |
2008-02-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
|
KR20090042973A
(ko)
|
2006-08-17 |
2009-05-04 |
베링거 인겔하임 인터내셔날 게엠베하 |
바이러스 폴리머라제 억제제
|
US8343477B2
(en)
|
2006-11-01 |
2013-01-01 |
Bristol-Myers Squibb Company |
Inhibitors of hepatitis C virus
|
US7772180B2
(en)
|
2006-11-09 |
2010-08-10 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
EA201101492A1
(ru)
|
2006-11-15 |
2012-09-28 |
Вирокем Фарма Инк. |
Аналоги тиофена для лечения или предупреждения флавивирусных инфекций
|
US7763584B2
(en)
|
2006-11-16 |
2010-07-27 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7888464B2
(en)
|
2006-11-16 |
2011-02-15 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8003604B2
(en)
|
2006-11-16 |
2011-08-23 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
AR068794A1
(es)
|
2007-06-29 |
2009-12-09 |
Gilead Sciences Inc |
Compuestos antivirales
|
AP2874A
(en)
|
2007-06-29 |
2014-03-31 |
Gilead Sciences Inc |
Antiviral compounds
|
WO2009018657A1
(en)
|
2007-08-03 |
2009-02-12 |
Boehringer Ingelheim International Gmbh |
Viral polymerase inhibitors
|
CA2708150A1
(en)
|
2007-12-05 |
2009-06-18 |
Enanta Pharmaceuticals, Inc. |
Fluorinated tripeptide hcv serine protease inhibitors
|
EP2234977A4
(en)
|
2007-12-19 |
2011-04-13 |
Boehringer Ingelheim Int |
VIRAL POLYMERASE INHIBITORS
|
US8202996B2
(en)
|
2007-12-21 |
2012-06-19 |
Bristol-Myers Squibb Company |
Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
|
US8163921B2
(en)
|
2008-04-16 |
2012-04-24 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7964560B2
(en)
|
2008-05-29 |
2011-06-21 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
EP2300491B1
(en)
|
2008-05-29 |
2016-01-06 |
Bristol-Myers Squibb Company |
Hepatitis c virus inhibitors
|
US8207341B2
(en)
|
2008-09-04 |
2012-06-26 |
Bristol-Myers Squibb Company |
Process or synthesizing substituted isoquinolines
|
UY32099A
(es)
|
2008-09-11 |
2010-04-30 |
Enanta Pharm Inc |
Inhibidores macrocíclicos de serina proteasas de hepatitis c
|
EP2687526A1
(en)
|
2008-09-16 |
2014-01-22 |
Boehringer Ingelheim International Gmbh |
Crystalline forms of a 2-thiazolyl- 4-quinolinyl-oxy derivative, a potent HCV inhibitor
|
US8563505B2
(en)
|
2008-09-29 |
2013-10-22 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8044087B2
(en)
|
2008-09-29 |
2011-10-25 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
EP2341924A4
(en)
|
2008-10-02 |
2013-01-23 |
David Gladstone Inst |
METHOD FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS
|
US8283310B2
(en)
|
2008-12-15 |
2012-10-09 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
AU2010203656A1
(en)
|
2009-01-07 |
2011-07-21 |
Scynexis, Inc. |
Cyclosporine derivative for use in the treatment of HCV and HIV infection
|
CN102448458B
(zh)
|
2009-03-18 |
2015-07-22 |
小利兰·斯坦福大学理事会 |
治疗黄病毒科病毒感染的方法和组合物
|
TW201040181A
(en)
|
2009-04-08 |
2010-11-16 |
Idenix Pharmaceuticals Inc |
Macrocyclic serine protease inhibitors
|
US8512690B2
(en)
|
2009-04-10 |
2013-08-20 |
Novartis Ag |
Derivatised proline containing peptide compounds as protease inhibitors
|
CN102458444A
(zh)
|
2009-05-13 |
2012-05-16 |
英安塔制药有限公司 |
用作丙型肝炎病毒抑制剂的大环化合物
|
US9284307B2
(en)
|
2009-08-05 |
2016-03-15 |
Idenix Pharmaceuticals Llc |
Macrocyclic serine protease inhibitors
|
JP5476859B2
(ja)
*
|
2009-08-25 |
2014-04-23 |
住友化学株式会社 |
光学活性な1−アミノ−2−エテニルシクロプロパン−1−カルボン酸エチルまたはその酸付加塩の製造方法、およびその製造方法に用いられる中間体
|
AU2010326225A1
(en)
|
2009-11-25 |
2012-06-07 |
Vertex Pharmaceuticals Incorporated |
5-alkynyl-thiophene-2-carboxylic acid derivatives and their use for the treatment or prevention of flavivirus infections
|
MX2012007420A
(es)
|
2009-12-24 |
2012-07-23 |
Vertex Pharma |
Analogos para el tratamiento o prevencion de infecciones de flavivirus.
|
AU2011209051B2
(en)
|
2010-01-27 |
2015-01-15 |
AB Pharma Ltd. |
Polyheterocyclic compounds highly potent as HCV inhibitors
|
EP2550267A1
(en)
|
2010-03-24 |
2013-01-30 |
Vertex Pharmaceuticals Incorporated |
Analogues for the treatment or prevention of flavivirus infections
|
EP2550262A1
(en)
|
2010-03-24 |
2013-01-30 |
Vertex Pharmaceuticals Incorporated |
Analogues for the treatment or prevention of flavivirus infections
|
TW201141857A
(en)
|
2010-03-24 |
2011-12-01 |
Vertex Pharma |
Analogues for the treatment or prevention of flavivirus infections
|
JP2013522377A
(ja)
|
2010-03-24 |
2013-06-13 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
フラビウイルス感染を処置または予防するためのアナログ
|
WO2011156545A1
(en)
|
2010-06-09 |
2011-12-15 |
Vertex Pharmaceuticals Incorporated |
Viral dynamic model for hcv combination therapy
|
EP2582717A2
(en)
|
2010-06-15 |
2013-04-24 |
Vertex Pharmaceuticals Incorporated |
Hcv ns5b polymerase mutants
|
WO2012006060A1
(en)
|
2010-06-28 |
2012-01-12 |
Vertex Pharmaceuticals Incorporated |
Compounds and methods for the treatment or prevention of flavivirus infections
|
WO2012006070A1
(en)
|
2010-06-28 |
2012-01-12 |
Vertex Pharmaceuticals Incorporated |
Compounds and methods for the treatment or prevention of flavivirus infections
|
AU2011276526A1
(en)
|
2010-06-28 |
2013-01-10 |
Vertex Pharmaceuticals Incorporated |
Compounds and methods for the treatment or prevention of Flavivirus infections
|
EP2606041A2
(en)
|
2010-08-17 |
2013-06-26 |
Vertex Pharmaceuticals Incorporated |
Compounds and methods for the treatment or prevention of flaviviridae viral infections
|
SI2618831T1
(sl)
|
2010-09-21 |
2016-06-30 |
Enanta Pharmaceuticals, Inc. |
Makrociklični inhibitorji proteaze HCV na osnovi prolina
|
BR112013008510A2
(pt)
|
2010-10-08 |
2016-07-05 |
Novartis Ag |
vitamina e formulações de inibidores de sulfamida ns3
|
CN103534256B
(zh)
|
2010-12-30 |
2016-08-10 |
益安药业 |
大环丙型肝炎丝氨酸蛋白酶抑制剂
|
KR20140003521A
(ko)
|
2010-12-30 |
2014-01-09 |
이난타 파마슈티칼스, 인코포레이티드 |
페난트리딘 매크로사이클릭 c형 간염 세린 프로테아제 억제제
|
TW201309690A
(zh)
|
2011-02-10 |
2013-03-01 |
Idenix Pharmaceuticals Inc |
巨環絲胺酸蛋白酶抑制劑,其醫藥組合物及其於治療hcv感染之用途
|
WO2012107589A1
(en)
|
2011-02-11 |
2012-08-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
|
WO2012121068A1
(ja)
*
|
2011-03-10 |
2012-09-13 |
住友化学株式会社 |
光学活性1-アミノ-2-ビニルシクロプロパンカルボン酸エステルの製造方法
|
US8957203B2
(en)
|
2011-05-05 |
2015-02-17 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US10201584B1
(en)
|
2011-05-17 |
2019-02-12 |
Abbvie Inc. |
Compositions and methods for treating HCV
|
US8691757B2
(en)
|
2011-06-15 |
2014-04-08 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
WO2012171332A1
(zh)
|
2011-06-16 |
2012-12-20 |
爱博新药研发(上海)有限公司 |
抑制丙型肝炎病毒的大环状杂环化合物及其制备和应用
|
CN102807607B
(zh)
*
|
2011-07-22 |
2013-10-23 |
爱博新药研发(上海)有限公司 |
抑制丙肝病毒的稠环杂环类化合物、其中间体及其应用
|
WO2013016499A1
(en)
|
2011-07-26 |
2013-01-31 |
Vertex Pharmaceuticals Incorporated |
Methods for preparation of thiophene compounds
|
AR087345A1
(es)
|
2011-07-26 |
2014-03-19 |
Vertex Pharma |
Metodos para la preparacion de compuestos de tiofeno
|
EP2787999B1
(en)
|
2011-12-06 |
2019-01-23 |
The Board of Trustees of The Leland Stanford Junior University |
Methods and compositions for treating viral diseases
|
US9012427B2
(en)
|
2012-03-22 |
2015-04-21 |
Alios Biopharma, Inc. |
Pharmaceutical combinations comprising a thionucleotide analog
|
JP6154474B2
(ja)
|
2012-10-19 |
2017-06-28 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
C型肝炎ウイルス阻害剤
|
US9643999B2
(en)
|
2012-11-02 |
2017-05-09 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US9334279B2
(en)
|
2012-11-02 |
2016-05-10 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US9598433B2
(en)
|
2012-11-02 |
2017-03-21 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
EP2914614B1
(en)
|
2012-11-05 |
2017-08-16 |
Bristol-Myers Squibb Company |
Hepatitis c virus inhibitors
|
WO2014134251A1
(en)
|
2013-02-28 |
2014-09-04 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions
|
EP2964664B1
(en)
|
2013-03-07 |
2017-01-11 |
Bristol-Myers Squibb Company |
Hepatitis c virus inhibitors
|
WO2014138374A1
(en)
|
2013-03-08 |
2014-09-12 |
Boehringer Ingelheim International Gmbh |
Oral combination therapy for treating hcv infection in specific patient sub-population
|
WO2015103490A1
(en)
|
2014-01-03 |
2015-07-09 |
Abbvie, Inc. |
Solid antiviral dosage forms
|
EP2899207A1
(en)
|
2014-01-28 |
2015-07-29 |
Amikana.Biologics |
New method for testing HCV protease inhibition
|
KR20210098504A
(ko)
|
2018-12-04 |
2021-08-10 |
브리스톨-마이어스 스큅 컴퍼니 |
다중 동위원소체 반응 모니터링에 의한 샘플내 보정 곡선을 사용한 분석 방법
|
WO2023149981A1
(en)
*
|
2022-02-07 |
2023-08-10 |
Purdue Research Foundation |
Compounds for the treatment of sars
|